Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale

Cancer Immunology Immunotherapy

Volumn 45, Issue 1, 1997, Pages 1-9

  Livingston, Philip O ^a   Zhang, Shengle ^a   Lloyd, Kenneth O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; CARBOHYDRATE ANTIGEN; EDRECOLOMAB; EPITOPE; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GLYCOLIPID; INTERCELLULAR ADHESION MOLECULE 1; SIALIC ACID; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; CELLULAR IMMUNITY; CLINICAL TRIAL; FUCOSYLATION; GENE EXPRESSION; GLYCOSYLATION; HUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CARBOHYDRATE SEQUENCE; CARBOHYDRATES; HUMANS; IMMUNOTHERAPY; MOLECULAR SEQUENCE DATA;

EID: 0030752033     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050394     Document Type: Review

References (74)

1. Livingston PO, Oettgen HF, Old LJ (1982) Specific active immunotherapy in cancer therapy. In: Immunological aspects of cancer therapeutics. Wiley, New York, 363-404
2. Livingston PO (1991) Active specific immunotherapy in the treatment of cancer. In: Oettgen HF (ed) Immunology and allergy clinics of north America. Human cancer immunology. II, vol 11. Saunders, London, pp 402-423
3. Brystryn JC, Ferrone S, Livingston PO (1993) Specific immunotherapy of cancer with vaccines. Ann NY Acad Sci 690
4. Livingston P (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147-166
5. Old LJ (1981) Cancer immunology: the search for specificity. G. H. A. Clowes Memorial Lecture. Cancer Res 41:361-375
6. AAP (1992) Universal hepatitis B immunization. Pediatrics 89:795-800
7. Fishbein DB, Robinson LE (1993) Rabies. N Engl J Med 329:1632-1638
8. Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9:78
9. Rohrer JW, Rohrer SD, Barsoum A, Coggin JH Jr (1994) Differential recognition of murine tumor-associated oncofetal transplantation antigen and individually specific transplantation antigens by syngeneic cloned BALB/c and RFM mouse T cells. J Immunol 152:754
10. Wilson RE, Hager EB, Hampers CI, et al. (1968) Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med 278:479
11. Zukoski CF, Killen DA, Ginn E, et al. (1970) Transplanted carcinoma in immunosuppressed patients. Transplantation 9:71
12. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254
13. Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettgen HF, Old LJ (1989) Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-7050
14. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968
15. Livingston PO (1997) The case for melanoma vaccines that induce antibodies. In: Kirkwood JM (ed) Molecular diagnosis, prevention and treatment of melanoma.(in press)
16. Darnell RB (1996) Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 93:4529-4536
17. Dalmau J, Graus F, Cheung N-K V, Rosenblum MK, Ho A, Canete A, Delattre J-Y, Thompson SJ, Posner JB (1995) Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 75:99-109
18. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G (1994) Improved survival in stage II melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044
19. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, Carbone DP (1993) Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Association with improved survival. J Natl Cancer Inst, 85:2012-2018
20. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, The German Cancer Aid 17-1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177-1183
21. Lin R-H, Mamula MJ, Hardin JA, Janeway CA Jr (1991) Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med 173:1433-1439
22. Serreze DV, Chapman HD, Varnum DS, Hanson MS, Reifsnyder PC, Richard SD, Fleming SA, Leiter EH, Shultz LD(1996) B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Igμnull mice. J Exp Med 184:2049-2053
23. Flexner S (1913) The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 17:553
24. Heidelberger M, Avery OT (1923) The soluble specific substance of pneumococcus. J Exp Med 38:73-79
25. Kayhty H, Peltola H, Karanko V, et al. (1983) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147:1100
26. Davidson NE, Gelmann EP, Lippman ME, Dickson RB (1987) Epidermal growth factor gene expression in estrogen-positive and negative human breast cancer cell lines. Mol End 1:216-223
27. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: (1993) Differential responses of human tumor cell lines to anti p185 HER2 monoclonal antibodies. Cancer Immol Immunother 37:255-263
28. Hamilton WB, Helling F, Lloyd KO, Livingston PO (1993) Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int J Cancer 53:566-573
29. Hamilton WB, Helling F, Livingston PO (1993) Ganglioside expression on sarcoma and small-cell lung carcinoma compared to tumors of neuroectodermal origin. Proc Am Assoc Cancer Res 34:491
30. Helling F, Livingston PO (1994) Ganglioside conjugate vaccines. Mol Chem Neuropathol 21:299-309
31. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL (1985) Immunogenicity of melanoma-associated ganliosides in cancer patients. Int J Cancer 35:607
32. Irie RF, Matsuki T, Morton DL (1989) Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786
33. Irie RF, Morton DL (1986) Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83:8694-8698
34. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal antibody IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242-1246
35. Dippold WG, Bernhard H, Peter Dienes H, Meyer zum Buschenfelde K-H (1988) Treatment of patients with malignant melanoma by monoclonal ganglioside antibodies. Eur J Cancer Clin Oncol 24:S65-S67
36. Raymond J, Kirkwood J, Vlock D, Rabkin M, Day R, Whiteside T, Herberman R, Mascari R, Simon B (1988) A phase 1B trial of murine monoclonal antibody R24 (anti-GD3) in metastatic melanoma (abstract). Proc Am Soc Clin Oncol 7:A958
37. Cheung N-K V, Lazarus H, Miraldi FD, Abramowsky CR, Kallie S, Saarinen UM, Spitzer T, Strandjord SE, Cocci PF, Berger NA (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440
38. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E. Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, LoBuglio AF (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14G9a in metastatic melanoma. Cancer Res 52:4342
39. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S-I, Kim YS (1990) Sialosyl Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66:1960-1966
40. Collier BD, Abdel-Nabi H, Doerr RJ, Harwood SJ, Olsen J, Kaplan EH, Winzelberg GG, Grossman SJ, Krag DN, Michell EP (1992) Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 185:179-186
41. Fung PYS, Madej M, Koganty RR, Longenecker BM (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50:4308-4314
42. Singhal A, Fohn M, Hakomori S-I (1991) Induction of a-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 51:1406-1411
43. MacLean GD, Reddish MA, Koganty RR, Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic sTn vaccine. J Immunol 19:59-68
44. Lloyd KO (1987) Blood group antigens as markers for normal differentiation and malignant change in human tissues. Am J Clin Pathol 87:129-139
45. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VI, Lloyd KO, Livingston PO (1997) Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int J Cancer (in press)
46. Kudryashov V, Ragupathi G, , Kim IJ, Livingston PO, Danishefsky SJ, Lloyd KO (1997) Immunogenicity of synthetic Lewis Y oligosaccharide-protein conjugates in mice: towards the design of anti-cancer vaccines. Cancer Immunol Immunother (in press)
47. Ragupathi G, Park TK, Zhang S, Kim IJ, Graeber K, Adluri S, Lloyd KO. Danishefsky SJ, Livingston PO (1997) Immunization of mice with the synthetic hexasaccaride Globo H results in antibodies against human cancer cells. Angew Chem 36:125-128
48. Nilsson O, Brezicka FT, Holmgren J, Sorenson S, Svennerholm L, Yngvason F, Lindholm L (1986) Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1. Cancer Res 46:1403-1407
49. Bilodeau, MT, Park, T-K, Hu, S, Randolph, JT, Danishefsky, SJ, Livingston, PO, Zhang S (1995) Total synthesis of a human breast tumor associated antigen. J Amer Chem Soc 117:7840-7841
50. Komminoth P, Roth J, Lackie PM, Bitter-Suermann D, Heitz PU (1991) Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. Am J Pathol 139:297-304
51. Kaufmann SHE (1996) Gamma/delta and other unconcentianal T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA 93:2272-2279
52. Haurum JS, Arsequell G, Lellouch AC, Wong, SYC, Dwek RA, MKcMichael AJ, Elliott T (1994) Recognition of carbohydrate by major histocompatibility comples class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 180:739-744
53. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R (1994) T cell recognition of carbohydrates on type II collagen. J Exp Med 180:745-749
54. Ishioka GY, Lamont AG, Thomson D, Bulbow N, Gaeta FCA, Sette A, Grey HM (1992) MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol 148:2446-2451
55. Eskola J, Kayrty H, Takuia AK, Peltola H, Ronneberg PR, Kha E, Pekkanen E, McVerry PH, Makela PH (1990) A randomized prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 323:1381-1387
56. Varki A (1993) Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 3:97-130
57. Kobata A (1992) Structures and functions of the sugar chains of glycoproteins. Eur J Biochem 209:483-501
58. Hart GW (1992) Glycosylation. Curr Opin Cell Biol 4:1017-1023
59. Ashwell G, Harford J (1982) Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51:531-554
60. Rosen SD, Bertozzi CR (1994) The selectins and their ligands. Curr Opin Cell Biol 6:663-673
61. Keim S, Schauer R, Crocker PR (1996) The sialoadhesins - a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily. Glycoconjugate J 13:913-926
62. Sawada R, Tsuboi S, Fukuda M. (1994) Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 269:1425-1431
63. Hakomori S-I (1996) Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 56:5309-5318
64. Cheresh DA, Harper JR, Schulz G, Reisfeld RA (1984) Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81:5767-5771
65. Nakano J, Raj BKM, Asagami C, Lloyd KO (1996) Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics. J Invest Dermatol 107:543-548
66. Tsuchida T, Saxton RE, Kmorton DL, et al. (1987) Gangliosides of human melanoma. J Natl Cancer Inst 78:45-54
67. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (in press)
68. Springer GF (1984) T and Tn, general carcinoma autoantigens. Science 224:1198-1206
69. Adluri S, Helling F, Calves MJ, Lloyd KO, Livingston PO (1995) Immunogenicity of synthetic TF- and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41:185-192
70. Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C (1995) Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J Immunother 17:151-180
71. Capurro M, Bover L, Portela P, Livingston PO, Mordoh J (1997) FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis X hapten. Cancer Immunol Immunother (in press)
72. 2 expression in the human nervous system and in neuroblastomas - an immunohistochemical study. Intl J Oncol 3:909-915
73. 3 ganglioside with CD45RO in resting and activated human T lymphocytes. Cell Immunol 173:131-148
74. Sopori ML, Donaldson LA, Savage SM (1990) T Lympocyte heterogeneity in the rat. III. Autoreactive T cells are activated by B cells. Cell Immun 128:427-437